Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 3
2024 9
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS. Llovet JM, et al. Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. doi: 10.1038/s41571-024-00868-0. Epub 2024 Feb 29. Nat Rev Clin Oncol. 2024. PMID: 38424197 Free PMC article. Review.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH. Singal AG, et al. Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22. Hepatology. 2023. PMID: 37199193 Free PMC article. No abstract available.
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, Northcott J, Lyle J, Rochestie S, Peters J, Connor JT, Jaffee EM, Csiki I, Weiner DB, Perales-Puchalt A, Sardesai NY. Yarchoan M, et al. Nat Med. 2024 Apr;30(4):1044-1053. doi: 10.1038/s41591-024-02894-y. Epub 2024 Apr 7. Nat Med. 2024. PMID: 38584166 Free PMC article. Clinical Trial.
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma.
Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, Howe K, Bendinelli KJ, Kartalia E, Qi H, Mo G, Montagne J, Leatherman JM, Lopez-Vidal TY, Zhu Q, Huff AL, Yuan X, Hernandez A, Coyne EM, Zaidi N, Zabransky DJ, Engle LL, Ogurtsova A, Baretti M, Laheru D, Durham JN, Wang H, Sunshine JC, Johnston RJ, Deutsch JS, Taube JM, Anders RA, Jaffee EM, Fertig EJ, Yarchoan M. Shu DH, et al. Nat Immunol. 2024 Nov;25(11):2110-2123. doi: 10.1038/s41590-024-01992-w. Epub 2024 Oct 25. Nat Immunol. 2024. PMID: 39455893
Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic responders.
Sidiropoulos DN, Shin SM, Wetzel M, Girgis AA, Bergman D, Danilova L, Perikala S, Shu DH, Montagne JM, Deshpande A, Leatherman J, Dequiedt L, Jacobs V, Ogurtsova A, Mo G, Yuan X, Lvovs D, Stein-O'Brien G, Yarchoan M, Zhu Q, Harper EI, Weeraratna AT, Kiemen AL, Jaffee EM, Zheng L, Ho WJ, Anders RA, Fertig EJ, Kagohara LT. Sidiropoulos DN, et al. bioRxiv [Preprint]. 2024 Sep 23:2024.09.22.613714. doi: 10.1101/2024.09.22.613714. bioRxiv. 2024. PMID: 39386736 Free PMC article. Preprint.
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.
D'Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, Pai M, Goldin RD, Ward SC, Fiel MI, Shu DH, Su YY, Cortellini A, Baretti M, Anders R, Yarchoan M, Hsu C, Marron TU, Pinato DJ. D'Alessio A, et al. Lancet Oncol. 2024 Nov;25(11):1465-1475. doi: 10.1016/S1470-2045(24)00457-1. Epub 2024 Oct 19. Lancet Oncol. 2024. PMID: 39437804 Free PMC article.
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.
Nakazawa M, Fang M, Vong T, Zorzi J, Griffith P, Anders RA, Oshima K, Kim AK, Laurin J, Lafaro KJ, Shubert CR, Burns WR, He J, Burkhart RA, Philosophe B, Meyer J, Liddell RP, Georgiades C, Hong K, Ho WJ, Baretti M, Strauss AT, Yarchoan M. Nakazawa M, et al. Cancer Res Commun. 2024 Aug 1;4(8):2123-2132. doi: 10.1158/2767-9764.CRC-24-0151. Cancer Res Commun. 2024. PMID: 39142659 Free PMC article.
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM, Crawford JC, Chou CH, Guy C, Pandey K, Kozlik T, Shah RK, Chung S, Nguyen P, Zhang X, Wang J, Bell M, Mettelman RC, Allen EK, Pogorelyy MV, Kim H, Minervina AA, Awad W, Bajracharya R, White T, Long D Jr, Gordon B, Morrison M, Glazer ES, Murphy AJ, Jiang Y, Fitzpatrick EA, Yarchoan M, Sethupathy P, Croft NP, Purcell AW, Federico SM, Stewart E, Gottschalk S, Zamora AE, DeRenzo C, Strome SE, Thomas PG. Kirk AM, et al. Cell Rep Med. 2024 Mar 19;5(3):101469. doi: 10.1016/j.xcrm.2024.101469. Cell Rep Med. 2024. PMID: 38508137 Free PMC article.
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade.
Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, Howe K, Bendinelli KJ, Qi H, Mo G, Montagne J, Leatherman JM, Lopez-Vidal TY, Zhu Q, Huff AL, Yuan X, Hernandez A, Coyne EM, Zaidi N, Zabransky DJ, Engle LL, Ogurtsova A, Baretti M, Laheru D, Durham JN, Wang H, Anders R, Jaffee EM, Fertig EJ, Yarchoan M. Shu DH, et al. bioRxiv [Preprint]. 2023 Oct 26:2023.10.16.562104. doi: 10.1101/2023.10.16.562104. bioRxiv. 2023. PMID: 37904980 Free PMC article. Preprint.
14 results